Multi centre, pilot phase II trial assessing the efficacy and safety of Bevacizumab + Gemcitabine + Carboplatin as first line treatment for patients diagnosed with Triple Negative Metastatic Breast Cancer.

Trial Profile

Multi centre, pilot phase II trial assessing the efficacy and safety of Bevacizumab + Gemcitabine + Carboplatin as first line treatment for patients diagnosed with Triple Negative Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Gemcitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2016 Time frame of the primary end point changed from 3 year to 1541 days and Gemcitabine Dosage changed from 100 mg/m2/dose to 1000 mg/m2/dose
    • 29 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top